Liquid Biopsies in Esophageal Cancer
ConditionEsophageal Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversitaire Ziekenhuizen KU Leuven
About this trial
Purpose of this study is to determine the value of liquid biopsies, e.g. testing of minimal residual disease (MRD) by using liquid biopsies to measure circulating tumour DNA (ctDNA) at diagnosis and during the multimodal and multidisciplinary curative-intent treatment of resectable esophageal cancer.
Eligibility criteria
Qualifiers
Male or female, age > 18 years
New diagnosis of esophageal cancer, pathologically confirmed squamous cell carcinoma (ESCC) or adenocarcinoma (EAC)
Clinically staged - cT1-4 N0-2 M0 (local or locally advanced, resectable)
Eligible for multidisciplinary treatment as assessed by MDT
Disqualifiers
(Oligo)metastatic disease
Histologically or cytologically confirmed diagnosis other than squamous cell carcinoma or adenocarcinoma (eg. neuroendocrine carcinoma, lymphoma…)
Other active malignancies
Previous exposure to chemoradiation (prior to MDT)
Trial design
Treatments tested in this trial
- Blood sample
Treatment groups
248 Participants
are divided into 3 treatment groupsSponsors and collaborators
Universitaire Ziekenhuizen KU Leuven
Lead sponsor
Kom Op Tegen Kanker
Collaborator
Source ClinicalTrials.gov